<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>17(6)</volume><submitter>Liisborg C</submitter><funding>Region Zealand&amp;apos;s research promotion fund</funding><funding>Fight for Sight Denmark</funding><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Peripheral T cell CXCR3 expression has been found uniquely lower in patients having neovascular age-related macular degeneration (nAMD) than in healthy individuals. The CXCR3-axis has been shown to have angiostatic and antifibrotic properties. We have recently investigated systemic markers in patients with myeloproliferative neoplasms (MPNs) because of their higher prevalence of AMD, and we have observed higher systemic chronic low-grade inflammation and immunosenescence signs in MPNs with drusen (MPNd) compared to those with normal retinas (MPNn). The MPNs evolve in a biological continuum from early cancer-stages (essential thrombocytosis, polycythemia vera) to the advanced myelofibrosis stage. Especially myelofibrosis is characterized by bone marrow angiogenesis and fibro</pubmed_abstract><journal>PloS one</journal><pagination>e0269960</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9202899</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers.</pubmed_title><pmcid>PMC9202899</pmcid><pubmed_authors>Kjær L</pubmed_authors><pubmed_authors>Lykke Sorensen T</pubmed_authors><pubmed_authors>Liisborg C</pubmed_authors><pubmed_authors>Skov V</pubmed_authors><pubmed_authors>Hasselbalch HC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers.</name><description>&lt;h4>Purpose&lt;/h4>Peripheral T cell CXCR3 expression has been found uniquely lower in patients having neovascular age-related macular degeneration (nAMD) than in healthy individuals. The CXCR3-axis has been shown to have angiostatic and antifibrotic properties. We have recently investigated systemic markers in patients with myeloproliferative neoplasms (MPNs) because of their higher prevalence of AMD, and we have observed higher systemic chronic low-grade inflammation and immunosenescence signs in MPNs with drusen (MPNd) compared to those with normal retinas (MPNn). The MPNs evolve in a biological continuum from early cancer-stages (essential thrombocytosis, polycythemia vera) to the advanced myelofibrosis stage. Especially myelofibrosis is characterized by bone marrow angiogenesis and fibro</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-05T13:32:56.143Z</modification><creation>2024-10-18T16:48:43.805Z</creation></dates><accession>S-EPMC9202899</accession><cross_references><pubmed>35709177</pubmed><doi>10.1371/journal.pone.0269960</doi></cross_references></HashMap>